SCHEMBL14730748

SCHEMBL14730748

CC1CC(C)(C)c2c([nH]c3ccc(C(=O)O)cc23)C1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 1/20 0.44
THRB P10828 1/20 0.44
HPGD P15428 1/20 0.44
KMT2A Q03164 1/20 0.44
GSK3B P49841 2/20 0.43
CCNB2 O95067 1/20 0.43
CDK1 P06493 1/20 0.43
CCNB1 P14635 1/20 0.43
CCNB3 Q8WWL7 1/20 0.43
MAPKAPK2 P49137 6/20 0.42
PPARG P37231 1/20 0.41
GSK3A P49840 1/20 0.40
CDK5 Q00535 1/20 0.40
CDK5R1 Q15078 1/20 0.40
KIF11 P52732 1/20 0.39
APEX1 P27695 1/20 0.39
PARP1 P09874 1/20 0.39
PTPN1 P18031 1/20 0.39
PTPN6 P29350 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14731426 0.87 KDM4E (0.43) KDM4EALDH1A1THRBHPGDKMT2A
SCHEMBL14730752 0.80 ALK (0.47) ALDH1A1KMT2AMAPKAPK2POLBMAPT
SCHEMBL14730689 0.79 KDM4E (0.47) KDM4EALDH1A1THRBHPGDKMT2A
SCHEMBL2996096 0.78 MAPKAPK2 (0.64) KDM4EALDH1A1THRBHPGDKMT2A
SCHEMBL3005560 0.78 KDM4E (0.46) KDM4EALDH1A1THRBHPGDKMT2A
SCHEMBL6070651 0.75 KMT2A (0.57) KDM4EALDH1A1THRBHPGDKMT2A
SCHEMBL14730707 0.71 MAPKAPK2 (0.42) KDM4EALDH1A1THRBHPGDKMT2A
SCHEMBL14730691 0.71 GSK3B (0.40) KDM4EALDH1A1THRBHPGDKMT2A
SCHEMBL14731498 0.71 KDM4E (0.51) KDM4EALDH1A1HPGDKMT2AGSK3B
SCHEMBL2987092 0.70 MAPKAPK2 (0.80) MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340539-B2 Hepatitis C inhibitor compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-17 US disclosed
US-9340539-B2 Hepatitis C inhibitor compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-17 US disclosed
US-20140343077-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-20 US disclosed
US-20140343077-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-20 US disclosed
WO-2013026163-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343077-A1 HEPATITIS C INHIBITOR COMPOUNDS HCCS, C1R, HAVCR2 KDM4E 4061/4885ALDH1A1 1605/4885THRB 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.